Step Therapy Requirements. Effective: 1/1/2019

Similar documents
AMANTADINE ER. Products Affected Step 2: OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE OSMOLEX ER 193 MG TABLET, Details

AMANTADINE ER. Products Affected Step 2: OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE OSMOLEX ER 193 MG TABLET, Details

AMANTADINE ER. Products Affected Step 2: OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE OSMOLEX ER 193 MG TABLET, Details

ANTIDEPRESSANTS. Details. dose pack Viibryd 10 mg tablet Viibryd 20 mg tablet Viibryd 40 mg tablet. Criteria

VNSNY CHOICE FIDA Complete Step Therapy Requirements. Effective: 04/01/2019

Step Therapy Requirements. Effective: 11/01/2018

Step Therapy Requirements. Effective: 05/01/2018

ANTICONVULSANTS. Details

ANTIDIABETIC AGENTS - MISCELLANEOUS

FirstCarolinaCare Insurance Company. Step Therapy Requirements

ANTICONVULSANTS. Details

ANTIDIABETIC AGENTS - MISCELLANEOUS

Santa Clara Family Health Plan Cal MediConnect Formulary. List of Step Therapy Requirements Effective: 12/01/ E

ANTIDIABETIC AGENTS - MISCELLANEOUS

Medicare Part D Drugs that Require Step Therapy Effective 12/01/2017

ANTICONVULSANTS. Details

ANTICONVULSANTS. Details

Step Therapy Requirements

VNSNY CHOICE FIDA Complete Step Therapy Requirements. Effective: 01/01/2017

VNSNY CHOICE FIDA Complete Step Therapy Requirements. Effective: 01/01/2017

Step Therapy Requirements. Effective: 12/01/2016

Step Therapy Requirements. Effective: 03/01/2015

FirstCarolinaCare Insurance Company Step Therapy Requirements

ANGIOTENSIN RECEPTOR BLOCKERS STEP THERAPY

ALLERGIC CONJUNCTIVITIS AGENTS

2017 Step Therapy Criteria

CRITERIA Trial of two generic formulary products from the following: atomoxetine or ADHD stimulant medication.

2018 Step Therapy Criteria

5-ASA. Products Affected DIPENTUM 250 MG CAPSULE LIALDA 1.2 GRAM TABLET,DELAYED RELEASE. Details

5-ASA. Products Affected. Details. Dipentum 250 mg capsule. Lialda 1.2 gram tablet,delayed release

ALPHA GLUCOSIDASE INHIBITOR THERAPY

JANUVIA 50 MG TABLET BYDUREON 2 MG/0.65 ML JARDIANCE 10 MG TABLET SUBCUTANEOUS PEN INJECTOR JARDIANCE 25 MG TABLET BYDUREON BCISE 2 MG/0.

WELLCARE/ OHANA HEALTH PLAN 2015 STEP THERAPY CRITERIA (No Changes Made Since: 08/2015)

ANTICONVULSANT STEP THERAPY

ABILIFY INJ. Products Affected Step 2: ABILIFY MAINTENA PREFILLED SYRINGE 300 MG INTRAMUSCULAR ABILIFY MAINTENA PREFILLED SYRINGE 400 MG INTRAMUSCULAR

5-ASA. Products Affected Dipentum 250 mg capsule. Details. Lialda 1.2 gram tablet,delayed release

Simply Step Therapy Document September 2018 Y0114_18_33074_I_009

HEALTHTEAM ADVANTAGE 2018 Step Therapy Criteria

HEALTHTEAM ADVANTAGE 2018 Step Therapy Criteria

Step Therapy Medications

ACYCLOVIR OINT (CCHP2017)

Harvard Pilgrim Health Care Stride SM Basic Rx (HMO), Stride SM Value Rx (HMO), Stride SM Value Rx Plus (HMO) and Stride SM Gain Rx (HMO)

Granite Alliance Insurance Company (PDP) 2018 Step Therapy Criteria Last Updated: 10/23/18

2018 Step Therapy FID 18088

Step Therapy Criteria 2019

Harvard Pilgrim Health Care Stride SM Basic Rx (HMO), Stride SM Value Rx (HMO) and Stride SM Value Rx Plus (HMO) Step Therapy Requirements

SelectHealth Advantage 2018 Step Therapy Criteria. Previous trial on at least ONE: Generic topical acne treatment. Previous trial on: alendronate

ACYCLOVIR OINT (CCHP2017)

Step Therapy Criteria

ADHD STIMULANTS-S(SHC)

ALBUTEROL - SCORE. Products Affected. Details. Step Therapy Criteria Optima Tier Gold Formulary Date Effective: November 1, 2018.

2018 PDP Premier Step Therapy Document September 2018 Y0114_18_33144_I_009

5-ASA. Products Affected Dipentum 250 mg capsule. Details. Lialda 1.2 gram tablet,delayed release

SelectHealth Advantage 2018 Step Therapy Criteria Previous trial on at least ONE: Generic topical acne treatment

**CRITERIA UNDER CMS REVIEW**

ALBUTEROL - SCORE. Products Affected. Details. Step Therapy Criteria Health Choice Generations 1 Tier Gold Effective Date: 11/01/2018.

ACYCLOVIR OINT (CCHP2017)

PPHP 2017 Formulary 2017 Step Therapy Criteria

CARE N CARE HEALTH PLAN

ACYCLOVIR OINT (CCHP2017)

ALBUTEROL - SCORE{XE "ALBUTEROL - SCORE"}

ADHD STIMULANTS - SCORE

2017 AlohaCare Advantage Plus Formulary (HMO SNP) Drugs with Step Therapy Requirements

2018 STEP THERAPY CRITERIA UCare Connect (SNBC) MinnesotaCare Prepaid Medical Assistance Program (PMAP) Minnesota Senior Care Plus (MSC+)

ANTIDEPRESSANTS. Details. Step Therapy 2018 Last Updated: 8/21/2018

2015 Step Therapy Prior Authorization Medical Necessity Guidelines

SelectHealth Advantage 2019 Step Therapy Criteria Previous trial on at least ONE: Generic topical acne treatment

ANTICONVULSANTS. Details. Step Therapy Criteria Date Effective: April 1, 2019

ATYPICAL ANTIPSYCHOTICS

DIFICID. Products Affected Step 2: DIFICID TABLET 200 MG ORAL. Details

2019 Simply Step Therapy Document

ADHD STIMULANTS - SCORE

Judges Reference Table for the March 2016 Psychotropic Medication Utilization Parameters for Foster Children

ALBUTEROL - SCORE. Products Affected. Details. Step Therapy Criteria Farm Bureau Health Plans Date Effective: November 1, 2018.

Relative Cost/Month. Less than $10. Loratadine Liquid* $10-$15 Cetirizine liquid 1mg/mL*

Step Therapy Group Algorithm Steps

Y0133_StepTherapyCriteria _C 10/18/18 Y0133_StepTherapyCriteria _C es 10/18/18

CARE N CARE HEALTH PLAN

2019 PDP Basic Step Therapy Document

ANTICONVULSANT THERAPY

ALBUTEROL - SCORE. Products Affected. Details. Step Therapy Criteria Golden State Medicare Health Plan, Golden (HMO) Last Updated: 09/01/2018

CARE N CARE HEALTH PLAN

2019 STEP THERAPY CRITERIA UCare Individual & Family Plans UCare Individual & Family Plans with Fairview

Transcription:

Effective: 1/1/2019 Updated 1/2019

AMANTADINE ER Sharp Health Plan (HMO) OSMOLEX ER 129 MG, EXTENDED RELEASE OSMOLEX ER 193 MG, EXTENDED RELEASE OSMOLEX ER 258 MG, EXTENDED RELEASE PRIOR CLAIM FOR AMANTADINE HCL IMMEDIATE RELEASE WITHIN THE PAST 120 DAYS. 2

ANTIDEPRESSANTS Sharp Health Plan (HMO) TRINTELLIX 10 MG TRINTELLIX 20 MG TRINTELLIX 5 MG VIIBRYD 10 MG (7)-20 MG (23) S IN A DOSE PACK VIIBRYD 10 MG VIIBRYD 20 MG VIIBRYD 40 MG PRIOR CLAIM FOR FORMULARY VERSION OF PAROXETINE, FLUOXETINE, SERTRALINE, DULOXETINE, CITALOPRAM, MIRTAZAPINE, ESCITALOPRAM, OR BUPROPION WITHIN THE PAST 120 DAYS. 3

ANTIDIABETIC AGENTS - MISCELLANEOUS GLYXAMBI 10 MG-5 MG GLYXAMBI 25 MG-5 MG INVOKAMET 150 MG-1,000 MG INVOKAMET 150 MG-500 MG INVOKAMET 50 MG-1,000 MG INVOKAMET 50 MG-500 MG INVOKAMET XR 150 MG-1,000 MG, EXTENDED RELEASE INVOKAMET XR 150 MG-500 MG, EXTENDED RELEASE INVOKAMET XR 50 MG-1,000 MG, EXTENDED RELEASE INVOKAMET XR 50 MG-500 MG, EXTENDED RELEASE INVOKANA 100 MG INVOKANA 300 MG JARDIANCE 10 MG JARDIANCE 25 MG SYNJARDY 12.5 MG-1,000 MG SYNJARDY 12.5 MG-500 MG SYNJARDY 5 MG-1,000 MG SYNJARDY 5 MG-500 MG SYNJARDY XR 10 MG-1,000 MG, EXTENDED RELEASE SYNJARDY XR 12.5 MG-1,000 MG, EXTENDED RELEASE SYNJARDY XR 25 MG-1,000 MG, EXTENDED RELEASE SYNJARDY XR 5 MG-1,000 MG, EXTENDED RELEASE PRIOR CLAIM FOR METFORMIN, METFORMIN ER, A SULFONYLUREA AGENT (GLYBURIDE, GLIPIZIDE, GLIMEPIRIDE, TOLAZAMIDE), PIOGLITAZONE, OR COMBINATION OF A SULFONYLUREA-METFORMIN WITHIN THE PAST 120 DAYS. 4

ANTI-INFLAMMATORY AGENTS - GI DIPENTUM 250 MG CAPSULE PRIOR CLAIM FOR ANY 1 OF THE FOLLOWING: BALSALAZIDE, APRISO, DELZICOL, MESALAMINE DR 800 MG TAB, OR FORMULARY MESALAMINE 1.2 G DR TAB WITHIN THE PAST 120 DAYS. 5

ANTIPSYCHOTIC AGENTS aripiprazole 10 mg disintegrating tablet aripiprazole 15 mg disintegrating tablet clozapine 100 mg disintegrating tablet clozapine 12.5 mg disintegrating tablet clozapine 150 mg disintegrating tablet clozapine 200 mg disintegrating tablet clozapine 25 mg disintegrating tablet FANAPT 1 MG FANAPT 10 MG FANAPT 12 MG FANAPT 1MG(2)-2 MG(2)-4MG(2)-6 MG(2) S IN A DOSE PACK FANAPT 2 MG FANAPT 4 MG FANAPT 6 MG FANAPT 8 MG SAPHRIS (BLACK CHERRY) 10 MG SUBLINGUAL SAPHRIS (BLACK CHERRY) 5 MG SUBLINGUAL SAPHRIS 10 MG SUBLINGUAL SAPHRIS 2.5 MG SUBLINGUAL SAPHRIS 5 MG SUBLINGUAL VERSACLOZ 50 MG/ML ORAL SUSPENSION VRAYLAR 1.5 MG (1)-3 MG (6) CAPSULES IN A DOSE PACK VRAYLAR 1.5 MG CAPSULE VRAYLAR 3 MG CAPSULE VRAYLAR 4.5 MG CAPSULE VRAYLAR 6 MG CAPSULE PRIOR CLAIM FOR FORMULARY VERSIONS OF ANY TWO ORAL ANTIPSYCHOTICS: RISPERIDONE, CLOZAPINE, OLANZAPINE, IMMEDIATE RELEASE QUETIAPINE FUMARATE, ZIPRASIDONE, ARIPIPRAZOLE WITHIN THE PAST 365 DAYS. 6

ANTIPSYCHOTIC AGENTS II REXULTI 0.25 MG REXULTI 0.5 MG REXULTI 1 MG REXULTI 2 MG REXULTI 3 MG REXULTI 4 MG PRIOR CLAIM FOR TWO (2) OF THE FOLLOWING FORMULARY ORAL VERSIONS OF ATYPICAL ANTIPSYCHOTICS (RISPERIDONE, CLOZAPINE, OLANZAPINE, QUETIAPINE, ARIPIPRAZOLE OR ZIPRASIDONE) OR SSRI (CITALOPRAM, ESCITALOPRAM, FLUOXETINE, PAROXETINE OR SERTRALINE) OR SNRI (DESVENLAFAXINE, DULOXETINE OR VENLAFAXINE) WITHIN THE PAST 365 DAYS 7

ANTIULCER AGENTS Sharp Health Plan (HMO) DEXILANT 30 MG CAPSULE, DELAYED RELEASE DEXILANT 60 MG CAPSULE, DELAYED RELEASE rabeprazole 20 mg tablet,delayed release PRIOR CLAIM FOR GENERIC FEDERAL LEGEND ORAL OMEPRAZOLE, PANTOPRAZOLE, OR LANSOPRAZOLE WITHIN THE PAST 120 DAYS. 8

B VERSUS D ADMINISTRATIVE STEP CYCLOPHOSPHAMIDE 25 MG CAPSULE CYCLOPHOSPHAMIDE 50 MG CAPSULE methotrexate sodium 2.5 mg tablet XATMEP 2.5 MG/ML ORAL SOLUTION IN ORDER TO ASSIST IN A PART B VS. D PAYMENT DETERMINATION, A PRIOR CLAIM SEEN FOR A RHEUMATOID ARTHRITIS, PSORIASIS OR ACTIVE POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS DRUG WITHIN THE PAST 120 DAYS WILL QUALIFY FOR PART D PAYMENT. ALL OTHER INDICATIONS WILL HAVE A PART B VS. D PAYMENT DETERMINATION MADE THROUGH THE FORMULARY EXCEPTION PROCESS PRIOR TO THE APPROVAL OF THE DRUG. 9

ELUXADOLINE VIBERZI 100 MG VIBERZI 75 MG PRIOR CLAIM FOR DICYCLOMINE AND XIFAXAN 550MG WITHIN THE PAST 365 DAYS. 10

FIDAXOMICIN DIFICID 200 MG PRIOR CLAIM FOR ORAL VANCOMYCIN IN THE PAST 120 DAYS. 11

GABAPENTIN SR Sharp Health Plan (HMO) GRALISE 300 MG,EXTENDED RELEASE GRALISE 30-DAY STARTER PACK 300 MG (9)-600 MG (69),EXT. RELEASE GRALISE 600 MG,EXTENDED RELEASE PRIOR CLAIM FOR GABAPENTIN IMMEDIATE RELEASE WITHIN THE PAST 120 DAYS. 12

INSULIN/GLP-1 ANALOG SOLIQUA 100/33 100 UNIT-33 MCG/ML SUBCUTANEOUS INSULIN PEN XULTOPHY 100/3.6 100 UNIT-3.6 MG/ML (3 ML) SUBCUTANEOUS INSULIN PEN PRIOR CLAIM FOR 2 OF THE FOLLOWING (ONE FROM EACH GROUP): A) VICTOZA, LANTUS, TOUJEO, OR OZEMPIC AND B) METFORMIN, METFORMIN ER, SULFONYLUREA AGENT (GLYBURIDE, GLIPIZIDE, GLIMEPIRIDE, TOLAZAMIDE), COMBO SULFONYLUREA- METFORMIN, OR PIOGLITAZONE IN PAST 365 DAYS. 13

NOVEL ORAL ANTICOAGULANTS PRADAXA 110 MG CAPSULE PRADAXA 150 MG CAPSULE PRADAXA 75 MG CAPSULE PRIOR CLAIM FOR ELIQUIS AND XARELTO IN THE PAST 365 DAYS. 14

OPHTHALMIC ANTIHISTAMINES - NO OTC ALREX 0.2 % EYE DROPS,SUSPENSION BEPREVE 1.5 % EYE DROPS PRIOR CLAIM FOR FEDERAL LEGEND LEVOCETIRIZINE, CROMOLYN SODIUM, EPINASTINE, OR FORMULARY OLOPATADINE EYE DROPS WITHIN THE PAST 120 DAYS. 15

RENIN ANGIOTENSIN SYSTEM INHIBITORS TEKTURNA 150 MG TEKTURNA 300 MG TEKTURNA HCT 150 MG-12.5 MG TEKTURNA HCT 150 MG-25 MG TEKTURNA HCT 300 MG-12.5 MG TEKTURNA HCT 300 MG-25 MG PRIOR CLAIM FOR AN ANGIOTENSIN CONVERTING ENZYME INHIBITOR (ACE INHIBITOR), OR ACE INHIBITOR COMBINATION OR A GENERIC ANGIOTENSIN RECEPTOR BLOCKER (ARB), OR GENERIC ARB COMBINATION WITHIN THE PAST 120 DAYS. 16

SPRITAM SPRITAM 1,000 MG FOR ORAL SUSPENSION SPRITAM 250 MG FOR ORAL SUSPENSION SPRITAM 500 MG FOR ORAL SUSPENSION SPRITAM 750 MG FOR ORAL SUSPENSION PRIOR CLAIM FOR LEVETIRACETAM SOLUTION IN THE PAST 120 DAYS 17

INDEX A ALREX 0.2 % EYE DROPS,SUSPENSION... 15 aripiprazole 10 mg disintegrating tablet... 6 aripiprazole 15 mg disintegrating tablet... 6 B BEPREVE 1.5 % EYE DROPS... 15 C clozapine 100 mg disintegrating tablet... 6 clozapine 12.5 mg disintegrating tablet... 6 clozapine 150 mg disintegrating tablet... 6 clozapine 200 mg disintegrating tablet... 6 clozapine 25 mg disintegrating tablet... 6 CYCLOPHOSPHAMIDE 25 MG CAPSULE... 9 CYCLOPHOSPHAMIDE 50 MG CAPSULE... 9 D DEXILANT 30 MG CAPSULE, DELAYED RELEASE... 8 DEXILANT 60 MG CAPSULE, DELAYED RELEASE... 8 DIFICID 200 MG... 11 DIPENTUM 250 MG CAPSULE... 5 F FANAPT 1 MG... 6 FANAPT 10 MG... 6 FANAPT 12 MG... 6 FANAPT 1MG(2)-2 MG(2)-4MG(2)-6 MG(2) S IN A DOSE PACK... 6 FANAPT 2 MG... 6 FANAPT 4 MG... 6 FANAPT 6 MG... 6 FANAPT 8 MG... 6 G GLYXAMBI 10 MG-5 MG... 4 GLYXAMBI 25 MG-5 MG... 4 GRALISE 300 MG,EXTENDED RELEASE... 12 GRALISE 30-DAY STARTER PACK 300 MG (9)-600 MG (69),EXT. RELEASE... 12 GRALISE 600 MG,EXTENDED RELEASE... 12 I INVOKAMET 150 MG-1,000 MG... 4 INVOKAMET 150 MG-500 MG 4 INVOKAMET 50 MG-1,000 MG... 4 INVOKAMET 50 MG-500 MG. 4 INVOKAMET XR 150 MG-1,000 MG, EXTENDED RELEASE... 4 INVOKAMET XR 150 MG-500 MG, EXTENDED RELEASE... 4 INVOKAMET XR 50 MG-1,000 MG, EXTENDED RELEASE... 4 INVOKAMET XR 50 MG-500 MG, EXTENDED RELEASE... 4 INVOKANA 100 MG... 4 INVOKANA 300 MG... 4 J JARDIANCE 10 MG... 4 JARDIANCE 25 MG... 4 M methotrexate sodium 2.5 mg tablet... 9 O OSMOLEX ER 129 MG, EXTENDED RELEASE... 2 OSMOLEX ER 193 MG, EXTENDED RELEASE... 2 OSMOLEX ER 258 MG, EXTENDED RELEASE... 2 P PRADAXA 110 MG CAPSULE... 14 PRADAXA 150 MG CAPSULE... 14 PRADAXA 75 MG CAPSULE... 14 R rabeprazole 20 mg tablet,delayed release... 8 REXULTI 0.25 MG... 7 REXULTI 0.5 MG... 7 REXULTI 1 MG... 7 REXULTI 2 MG... 7 REXULTI 3 MG... 7 REXULTI 4 MG... 7 S SAPHRIS (BLACK CHERRY) 10 MG SUBLINGUAL... 6 18

SAPHRIS (BLACK CHERRY) 5 MG SUBLINGUAL... 6 SAPHRIS 10 MG SUBLINGUAL... 6 SAPHRIS 2.5 MG SUBLINGUAL... 6 SAPHRIS 5 MG SUBLINGUAL 6 SOLIQUA 100/33 100 UNIT-33 MCG/ML SUBCUTANEOUS INSULIN PEN... 13 SPRITAM 1,000 MG FOR ORAL SUSPENSION... 17 SPRITAM 250 MG FOR ORAL SUSPENSION... 17 SPRITAM 500 MG FOR ORAL SUSPENSION... 17 SPRITAM 750 MG FOR ORAL SUSPENSION... 17 SYNJARDY 12.5 MG-1,000 MG... 4 SYNJARDY 12.5 MG-500 MG. 4 SYNJARDY 5 MG-1,000 MG... 4 SYNJARDY 5 MG-500 MG... 4 SYNJARDY XR 10 MG-1,000 MG, EXTENDED RELEASE... 4 SYNJARDY XR 12.5 MG-1,000 MG, EXTENDED RELEASE... 4 SYNJARDY XR 25 MG-1,000 MG, EXTENDED RELEASE... 4 SYNJARDY XR 5 MG-1,000 MG, EXTENDED RELEASE... 4 T TEKTURNA 150 MG... 16 TEKTURNA 300 MG... 16 TEKTURNA HCT 150 MG-12.5 MG... 16 TEKTURNA HCT 150 MG-25 MG... 16 TEKTURNA HCT 300 MG-12.5 MG... 16 TEKTURNA HCT 300 MG-25 MG... 16 TRINTELLIX 10 MG... 3 TRINTELLIX 20 MG... 3 TRINTELLIX 5 MG... 3 V VERSACLOZ 50 MG/ML ORAL SUSPENSION... 6 VIBERZI 100 MG... 10 VIBERZI 75 MG... 10 VIIBRYD 10 MG (7)-20 MG (23) S IN A DOSE PACK... 3 VIIBRYD 10 MG... 3 VIIBRYD 20 MG... 3 VIIBRYD 40 MG... 3 VRAYLAR 1.5 MG (1)-3 MG (6) CAPSULES IN A DOSE PACK... 6 VRAYLAR 1.5 MG CAPSULE... 6 VRAYLAR 3 MG CAPSULE... 6 VRAYLAR 4.5 MG CAPSULE... 6 VRAYLAR 6 MG CAPSULE... 6 X XATMEP 2.5 MG/ML ORAL SOLUTION9 XULTOPHY 100/3.6 100 UNIT-3.6 MG/ML (3 ML) SUBCUTANEOUS INSULIN PEN... 13 19